Page last updated: 2024-08-21

fluorobenzenes and Bone Loss, Perimenopausal

fluorobenzenes has been researched along with Bone Loss, Perimenopausal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anastasilakis, AD; Bisbinas, I; Makras, P; Papapoulos, SE; Polyzos, SA; Sakellariou, GT	1

Trials

1 trial(s) available for fluorobenzenes and Bone Loss, Perimenopausal

Article	Year
No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcified tissue international, 2011, Volume: 88, Issue:5 Topics: Acute-Phase Reaction; Aged; Body Temperature; Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leukocyte Count; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Zoledronic Acid	2011

Article

Year

No effect of rosuvastatin in the zoledronate-induced acute-phase response.

Calcified tissue international, 2011, Volume: 88, Issue:5

Topics: Acute-Phase Reaction; Aged; Body Temperature; Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leukocyte Count; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Zoledronic Acid

2011